{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:43:20Z","timestamp":1788403400041,"version":"build-2803163510"},"reference-count":50,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","award":["APP1175929"],"award-info":[{"award-number":["APP1175929"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Non-melanomatous cutaneous spindle cell neoplasms are a rare group of malignancies that present a diagnostic challenge, and for which there is a lack of consensus on how to best manage patients with advanced disease and only limited reports of immune-checkpoint inhibitor (ICI) responses. In this study, we performed a single-center retrospective review of treatment outcomes for all advanced non-melanomatous cutaneous spindle cell neoplasms treated with ICIs. Blinded histopathology reviews occurred to confirm each diagnosis. Comprehensive tumour profiling included whole exome sequencing for tumour mutational burden (TMB) and ultraviolet(UV) signatures, and immunohistochemistry for immune-cell infiltration (CD4\/CD3\/CD8\/CD103\/CD20) and immune-checkpoint expression (PD-L1\/LAG3\/TIGIT). Seven patients were identified. The objective response rate was 86% (6\/7) with five complete responses (CR). Responses were durable with two patients in CR &gt; 30 months after ICI commencement. All patients had high TMB and UV signatures. One patient had PD-L1 100% (combined positive score) with abundant immune-cell infiltration and LAG3 expression. In advanced non-melanomatous cutaneous spindle cell neoplasms, excellent responses to ICIs with durable disease control were observed. ICIs are worthy of further exploration in these patients. UV signatures and high TMB could be used to help select patients for treatment.<\/jats:p>","DOI":"10.3390\/cancers16081452","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T03:07:48Z","timestamp":1712718468000},"page":"1452","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Retrospective Review and Comprehensive Tumour Profiling of Advanced Non-Melanomatous Cutaneous Spindle Cell Neoplasms Treated with Immune-Checkpoint Inhibitors"],"prefix":"10.3390","volume":"16","author":[{"given":"Luke S.","family":"McLean","sequence":"first","affiliation":[{"name":"The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3052, Australia"},{"name":"Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC 3052, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0777-2279","authenticated-orcid":false,"given":"Annette M.","family":"Lim","sequence":"additional","affiliation":[{"name":"The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3052, Australia"},{"name":"Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC 3052, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Angel","sequence":"additional","affiliation":[{"name":"Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC 3052, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Young","sequence":"additional","affiliation":[{"name":"Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC 3052, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Pizzolla","sequence":"additional","affiliation":[{"name":"Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC 3052, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Archer","sequence":"additional","affiliation":[{"name":"Monash Bioinformatics Platform, Melbourne, VIC 3168, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Solomon","sequence":"additional","affiliation":[{"name":"The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3052, Australia"},{"name":"Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC 3052, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alesha A.","family":"Thai","sequence":"additional","affiliation":[{"name":"The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3052, Australia"},{"name":"Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC 3052, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4305-117X","authenticated-orcid":false,"given":"Jeremy","family":"Lewin","sequence":"additional","affiliation":[{"name":"The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3052, Australia"},{"name":"Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC 3052, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Rischin","sequence":"additional","affiliation":[{"name":"The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3052, Australia"},{"name":"Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC 3052, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"958","DOI":"10.5858\/arpa.2018-0112-RA","article-title":"Cutaneous Spindle Cell Neoplasms: Pattern-Based Diagnostic Approach","volume":"142","author":"Choi","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/cup.12603","article-title":"Pleomorphic dermal sarcoma: A more aggressive neoplasm than previously estimated","volume":"43","author":"Pinedo","year":"2016","journal-title":"J. Cutan. Pathol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1097\/PAS.0b013e31825359e1","article-title":"Pleomorphic dermal sarcoma: Adverse histologic features predict aggressive behavior and allow distinction from atypical fibroxanthoma","volume":"36","author":"Miller","year":"2012","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"873771","DOI":"10.3389\/fonc.2022.873771","article-title":"Hemato-Oncological Diseases as Risk Factor for Recurrence or Metastasis of Pleomorphic Dermal Sarcoma","volume":"12","author":"Helbig","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_5","first-page":"235","article-title":"S1-guideline atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS)","volume":"20","author":"Helbig","year":"2022","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"975342","DOI":"10.3389\/fonc.2022.975342","article-title":"Immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas","volume":"12","author":"Helbig","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jaad.2023.08.050","article-title":"Atypical fibroxanthoma and pleomorphic dermal sarcoma: Local recurrence and metastasis in a nationwide population-based cohort of 1118 patients","volume":"89","author":"Abebe","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S1470-2045(19)30728-4","article-title":"Cemiplimab in locally advanced cutaneous squamous cell carcinoma: Results from an open-label, phase 2, single-arm trial","volume":"21","author":"Migden","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e002757","DOI":"10.1136\/jitc-2021-002757","article-title":"Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: Extended follow-up of outcomes and quality of life analysis","volume":"9","author":"Rischin","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1200\/JCO.19.03054","article-title":"Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)","volume":"38","author":"Grob","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1149106","DOI":"10.3389\/fonc.2023.1149106","article-title":"Therapeutic advances in leiomyosarcoma","volume":"13","author":"Lacuna","year":"2023","journal-title":"Front. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2324709619850216","DOI":"10.1177\/2324709619850216","article-title":"Prolonged Response to Pembrolizumab in Spindle Cell Squamous Cell Carcinoma Metastatic to the Central Nervous System","volume":"7","author":"Liu","year":"2019","journal-title":"J. Investig. Med. High Impact Case Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jdcr.2017.06.005","article-title":"Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade","volume":"3","author":"Miller","year":"2017","journal-title":"JAAD Case Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5638","DOI":"10.1158\/1078-0432.CCR-20-1899","article-title":"Integrative Analysis of Pleomorphic Dermal Sarcomas Reveals Fibroblastic Differentiation and Susceptibility to Immunotherapy","volume":"26","author":"Klein","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00262-019-02339-3","article-title":"Immune-phenotyping of pleomorphic dermal sarcomas suggests this entity as a potential candidate for immunotherapy","volume":"68","author":"Klein","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e1665977","DOI":"10.1080\/2162402X.2019.1665977","article-title":"First report on two cases of pleomorphic dermal sarcoma successfully treated with immune checkpoint inhibitors","volume":"8","author":"Klein","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1111\/bjd.19309","article-title":"Complete response of metastatic pleomorphic dermal sarcoma to anti-PD-1 therapy","volume":"183","author":"Klein","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"122s","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J. Nucl. Med."},{"key":"ref_22","unstructured":"Elder, D.E., Massi, D., Scolyer, R.A., and Willemze, R. (2023). WHO Classification of Skin Tumours."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1158\/2326-6066.CIR-17-0299","article-title":"Prognostic Significance of PD-L1(+) and CD8(+) Immune Cells in HPV(+) Oropharyngeal Squamous Cell Carcinoma","volume":"6","author":"Solomon","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1093\/annonc\/mdz271","article-title":"Identification of an excellent prognosis subset of human papillomavirus-associated oropharyngeal cancer patients by quantification of intratumoral CD103+ immune cell abundance","volume":"30","author":"Solomon","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_25","unstructured":"Agilent_Technologies (2019). PD-L1 IHC 22C3 pharmDx Interpretation Manual\u2014Head and Neck Squamous Cell Carcinoma (HNSCC), Agilent_Technologies."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nmeth.4197","article-title":"Salmon provides fast and bias-aware quantification of transcript expression","volume":"14","author":"Patro","year":"2017","journal-title":"Nat. Methods"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41587-020-0439-x","article-title":"The nf-core framework for community-curated bioinformatics pipelines","volume":"38","author":"Ewels","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3\u2013related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Foroutan, M., Bhuva, D.D., Lyu, R., Horan, K., Cursons, J., and Davis, M.J. (2018). Single sample scoring of molecular phenotypes. BMC Bioinform., 19.","DOI":"10.1186\/s12859-018-2435-4"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Hanssen, F., Garcia, M.U., Folkersen, L., Pedersen, A.S., Lescai, F., Jodoin, S., Miller, E., Seybold, M., Wacker, O., and Smith, N. (2023). Scalable and efficient DNA sequencing analysis on different compute infrastructures aiding variant discovery. bioRxiv, bioRxiv:2023.2007.2019.549462.","DOI":"10.1101\/2023.07.19.549462"},{"key":"ref_31","unstructured":"Li, H. (2013). Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1101\/gr.107524.110","article-title":"The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data","volume":"20","author":"McKenna","year":"2010","journal-title":"Genome Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4161\/fly.19695","article-title":"A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3","volume":"6","author":"Cingolani","year":"2012","journal-title":"Fly"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"18217","DOI":"10.1038\/s41598-020-75062-0","article-title":"MutSignatures: An R package for extraction and analysis of cancer mutational signatures","volume":"10","author":"Fantini","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"D941","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: The Catalogue Of Somatic Mutations In Cancer","volume":"47","author":"Tate","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1038\/s41388-018-0245-9","article-title":"APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer","volume":"37","author":"Wang","year":"2018","journal-title":"Oncogene"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.jid.2019.03.1163","article-title":"Genetic Mutations Underlying Phenotypic Plasticity in Basosquamous Carcinoma","volume":"139","author":"Chiang","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"7647","DOI":"10.2147\/IJGM.S335592","article-title":"CSMD3 is Associated with Tumor Mutation Burden and Immune Infiltration in Ovarian Cancer Patients","volume":"14","author":"Lu","year":"2021","journal-title":"Int. J. Gen. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41698-022-00292-6","article-title":"Favorable immune checkpoint inhibitor outcome of patients with melanoma and NSCLC harboring FAT1 mutations","volume":"6","author":"Zhang","year":"2022","journal-title":"NPJ Precis. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1158\/0008-5472.CAN-11-3218","article-title":"Immunotype and Immunohistologic Characteristics of Tumor-Infiltrating Immune Cells Are Associated with Clinical Outcome in Metastatic Melanoma","volume":"72","author":"Erdag","year":"2012","journal-title":"Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"15095","DOI":"10.1038\/ncomms15095","article-title":"Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer","volume":"8","author":"Carstens","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.annonc.2023.06.007","article-title":"Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia","volume":"34","author":"Cass","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e002345","DOI":"10.1136\/jitc-2021-002345","article-title":"Anti-PD-1 elicits regression of undifferentiated pleomorphic sarcomas with UV-mutation signatures","volume":"9","author":"Cheung","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-Term Outcomes with Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients with Advanced Melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40644-021-00426-2","article-title":"FDG-PET\/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma","volume":"21","author":"McLean","year":"2021","journal-title":"Cancer Imaging"},{"key":"ref_46","unstructured":"Mari\u00f1o-Enr\u00edquez, A., and Hornick, J.L. (2013). Practical Soft Tissue Pathology: A Diagnostic Approach E-Book: A Volume in the Pattern Recognition Series, Elsevier."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"Embo J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13046-020-01586-y","article-title":"Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy","volume":"39","author":"Galli","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"v477","DOI":"10.1093\/annonc\/mdz253.018","article-title":"1192O\u2014Association of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158","volume":"30","author":"Marabelle","year":"2019","journal-title":"Ann. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/8\/1452\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:25:23Z","timestamp":1760106323000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/8\/1452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,10]]},"references-count":50,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["cancers16081452"],"URL":"https:\/\/doi.org\/10.3390\/cancers16081452","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,10]]}}}